Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Geptanolimab - Apollomics

Drug Profile

Geptanolimab - Apollomics

Alternative Names: Aibining; APL-501; CBT 501; GB 226; Genolimzumab - Apollomics; Geptanolimab - Genor Biopharma; Recombinant humanised anti-PD-1 monoclonal antibody

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CBT Pharmaceuticals; Crown Bioscience
  • Developer Apollomics; Genor Biopharma; HUTCHMED
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Peripheral T-cell lymphoma
  • Phase III Cervical cancer
  • Phase II Alveolar soft part sarcoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I/II Liver cancer
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 23 Jan 2024 Phase-I development in Colorectal-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) is still ongoing in China (IV) (Genor Pharma pipeline, January 2024)
  • 23 Jan 2024 Phase-I development in Non-small-cell-lung-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) is still ongoing in China (IV) (Genor Pharma pipeline, January 2024)
  • 23 Jan 2024 Phase-III clinical trials in Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (Genor Pharma pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top